These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11996639)

  • 1. Trizivir.
    Keiser P; Nassar N
    Expert Opin Pharmacother; 2002 May; 3(5):619-24. PubMed ID: 11996639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.
    Keiser P; Nassar N
    Expert Opin Pharmacother; 2007 Mar; 8(4):477-83. PubMed ID: 17309342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.
    Katlama C; Fenske S; Gazzard B; Lazzarin A; Clumeck N; Mallolas J; Lafeuillade A; Mamet JP; Beauvais L;
    HIV Med; 2003 Apr; 4(2):79-86. PubMed ID: 12702127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lamivudine/zidovudine/abacavir: triple combination tablet.
    Ibbotson T; Perry CM
    Drugs; 2003; 63(11):1089-98; discussion 1099-1100. PubMed ID: 12749741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
    Shey M; Kongnyuy EJ; Shang J; Wiysonge CS
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005481. PubMed ID: 19588374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
    Fischl MA; Burnside AE; Farthing CE; Thompson MA; Bellos NC; Williams VC; Kauf TL; Wannamaker PG; Shaefer MS;
    Pharmacotherapy; 2003 Nov; 23(11):1432-40. PubMed ID: 14620390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abacavir sulfate, lamivudine, and zidovudine (Trizivir).
    Porche D
    J Assoc Nurses AIDS Care; 2001; 12(6):88-90. PubMed ID: 11723917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
    Cahn P; Vibhagool A; Schechter M; Soto-Ramirez L; Carosi G; Smaill F; Jordan JC; Pharo CE; Thomas NE; Steel HM
    Curr Med Res Opin; 2004 Jul; 20(7):1115-23. PubMed ID: 15265256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
    Vibhagool A; Cahn P; Schechter M; Smaill F; Soto-Ramirez L; Carosi G; Montroni M; Pharo CE; Jordan JC; Thomas NE; Pearce G
    Curr Med Res Opin; 2004 Jul; 20(7):1103-14. PubMed ID: 15265255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal study.
    Lafeuillade A; Clumeck N; Mallolas J; Jaeger H; Livrozet JM; Ferreira Mdo S; Johnson M; Cheret A; Antoun Z;
    HIV Clin Trials; 2003; 4(1):37-43. PubMed ID: 12577195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.
    Kessler HA
    MedGenMed; 2005 Jun; 7(2):70. PubMed ID: 16369448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
    AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
    Stürmer M; Dauer B; Moesch M; Haberl A; Mueller A; Locher L; Knecht G; Hanke N; Doerr HW; Staszewski S
    Antivir Ther; 2007; 12(1):25-30. PubMed ID: 17503744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.
    Katlama C; Gazzard B; Mallolas J; Schürmann D; Moroni M; Demonty N; Antoun Z; Gordon D
    AIDS; 2003 Aug; 17(12):1855-6. PubMed ID: 12891074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
    Mastroianni CM; d'Ettorre G; Vullo V
    Expert Opin Pharmacother; 2006 Nov; 7(16):2233-41. PubMed ID: 17059380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
    Yuen GJ; Lou Y; Thompson NF; Otto VR; Allsup TL; Mahony WB; Hutman HW
    J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.